When the Difficult Session Is the Most Important One: Rethinking "Bad Trips" in Ketamine Therapy
One of the questions I get most often from ketamine clinic owners and medical directors is some version of this: how can we support patients through hard sessions?
It's the right question. And the fact that more clinics are asking it tells me the field is maturing in important ways. But the answer is more nuanced, and more hopeful, than most providers expect.
What I've come to understand through years of specialized work in psychedelic-assisted therapy is that difficult sessions aren't the exception to good ketamine treatment. For a meaningful portion of patients, they're actually the center of it.
What the research tells us and what it actually means
Studies using psilocybin, one of the most rigorously studied psychedelic medicines, consistently find that approximately one in three participants reports a distressing experience. That figure has held across multiple research groups and contexts. It's not a red flag. It's a baseline clinical reality that anyone offering psychedelic-assisted treatment needs to plan for.
1 in 3 Patients report a distressing psychedelic experience (Griffiths et al., 2006; 2011)
62% Rank it among the top 10 most challenging experiences of their lives (Carbonaro et al., 2016)
80% Of those same patients report meaningful improvement in wellbeing afterward (Carbonaro et al., 2016)
That last number is the one worth sitting with. Eighty percent of patients who had what they would describe as a "bad trip" went on to report meaningful improvement in their wellbeing. That's not despite the difficulty. It's connected to it.
This pattern mirrors what we know from trauma research more broadly. People who move through genuinely challenging experiences and have the support to make sense of them often emerge with more clarity, more resilience, and more capacity for change than those who haven't encountered that kind of depth.
Why difficult sessions tend to be therapeutically significant
The clinical understanding I've developed, and that leading researchers like Robin Carhart-Harris have articulated, is that psychedelic medicines don't produce distress randomly. They tend to surface what is already present in the patient's inner world. The fear, the grief, the unprocessed material that emerges in a hard session is almost always connected to the very thing the patient came to treat in the first place.
A difficult session isn't a detour from the therapeutic work.
For many patients, it is the therapeutic work and a necessary confrontation with what has been driving their suffering all along.
That reframe changes everything about how a clinic should respond when a patient has a hard experience. The question stops being "how do we prevent this from happening again?" and becomes "how do we help this patient understand what happened and move through it?"
Where behavioral health support makes the difference
This is where I want to be direct about something, because I think it matters for how ketamine clinics think about their model.
Medical providers do essential work: calibrating dose, ensuring physiological safety, monitoring the experience in real time. None of what I'm describing diminishes that. But the psychological architecture of the ketamine experience like what a patient brings into the room with them, how they interpret what surfaces, and how they metabolize it afterward, sits in a different clinical lane. It requires a different kind of expertise and a different kind of relationship.
In my work as a virtual behavioral health partner to ketamine clinics, I'm not physically present during infusions. What I provide is the clinical infrastructure that surrounds the medical experience: preparation work that gives patients a psychological framework before their first session, ongoing availability to help clinic staff and patients navigate difficult material when it arises, and structured integration therapy that helps patients connect what emerged in the session to their broader treatment goals and daily life.
Clinics often ask me whether virtual support is sufficient for this kind of work. My honest answer is that the preparation and integration phases are highly effective in a telehealth format. And for those moments mid-protocol when a patient is struggling and needs immediate guidance, having an established therapeutic relationship already in place means they're not reaching out to a stranger. They're reaching out to someone who already knows their story.
The clinics that will lead this field
I've worked alongside a range of ketamine providers, and what I've observed is consistent: the practices that invest in behavioral health as a core part of their model see better protocol completion, stronger patient relationships, and a clinical reputation that compounds over time.
Referring physicians notice. Patients notice. And as this field matures and scrutiny increases, the standard of care will increasingly reflect what the research has been telling us all along.
The difficult session isn't the end of the story. With the right support structure, it's often where the most important work begins.
Thinking about adding behavioral health to your ketamine practice?
I work with ketamine clinics virtually to provide preparation, guidance through difficult experiences, and integration therapy designed to fit alongside your existing medical model without disrupting it.
If you're curious about what that looks like in practice, I'm always glad to have that conversation.
www.PsychThera.org · Trevor@PsychThera.org · (206) 413-8881